Comparison of Anti-Human CD38 Clones HB7 vs. HIT2

CD38 (NAD+ glycohydrolase) is a critical type II transmembrane protein that plays multiple essential roles within the human immune system.

It actively functions to activate, promote growth, and strictly guide the downstream development of mature lymphocytes, as well as trigger the programmed death (apoptosis) of specific myeloid and lymphoid precursor cells. Additionally, CD38’s robust enzymatic activity, physically located on its extracellular domain, successfully enables it to convert NAD+ directly into ADP-ribose, powerfully generate cyclic ADP-ribose (cADPR), and seamlessly break down cADPR.

These continuous metabolic processes heavily influence the local levels of metabolites intimately involved in calcium signaling. The ADP-ribose directly produced by CD38 acts as a key chemical signaling molecule strictly responsible for the targeted movement of active neutrophils and dendritic cells. Furthermore, CD38 serves as a highly reliable diagnostic marker for certain specific B cell populations and leukemia, acting as a massive target for cutting-edge immunotherapy in actively treating multiple myeloma.

1. Spotlight: Comparing Clones HB7 vs. HIT2

This application issue heavily focuses on evaluating two specific FITC-conjugated anti-CD38 antibodies meticulously derived from different laboratory clones: HB7 and HIT2. These robust antibodies were rigorously analyzed via flow cytometry to carefully compare their relative reactivity with various native populations of human peripheral blood leukocytes and active B cells.

2. Reactivity in Peripheral Blood Leukocytes

Flow cytometric analysis reveals the distinct reactivity and binding strength of both clones across different cellular populations.

Figure 1: Shows the reactivity patterns of FITC-labeled anti-CD38 clones HB7 and HIT2 with different native populations of human peripheral blood leukocytes. These distinct patterns effectively confirm the highly reliable performance of both independent clones across diverse cell types.

Figure 2: Reactivity of anti-CD38 clones HB7 and HIT2, directly labeled with FITC, is shown clearly on targeted B cells and carefully compared based on secondary CD27 expression.

Figure 3: The precise reactivity patterns of FITC-labeled anti-CD38 clones HB7 and HIT2 are shown reliably on isolated B cells, evaluated specifically relative to CD138 expression markers.

3. Conclusion & Products

Both the HB7 and HIT2 anti-CD38 clones exhibit remarkably strong, highly specific immunological reactivity, undeniably making them immensely valuable laboratory tools for both fundamental research and advanced clinical applications. Their flawless performance in reliably identifying complex leukocyte populations and specific B cell subsets confidently supports their continued widespread use in advanced studies of immune function and precise therapeutic targeting.

Below, you can easily explore both the unconjugated and FITC-conjugated versions of these highly validated Biorbyt antibodies: